- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04356885
COVID-19 and Psychotic Symptoms in France (SCHIZOVID-19)
Impact of Containment and Quarantine During COVID-19 Outbreack on Psychotic Symptoms in the General Population in France
Study Overview
Status
Conditions
Detailed Description
The pandemic of the novel coronavirus disease (COVID-19) has now affected millions of people, including people in France. There are reports in the media about increased stress, anxiety and isolation for the entire population. Likewise, there are many concerns regarding people with mental health issues including people experiencing psychotic symptoms. Thus, studies are needed to understand better the effects of the COVID-19 pandemic and related government measures (e.g., self-isolation) on the mental health and specifically on psychotic experiences. To reach this aim the investigators designed an online survey evaluating people's perceptions of the COVID-19 pandemic and government measures, their habits during the isolation period, to what extent they feel lonely, how they are managing their emotions, their general emotional state and finally the presence of psychotic experiences. Participants will be invited to complete these measures three times. Participants will complete the survey again in 1 week and then in 1 month.
The specific goals of this project are:
- Determine the association between psychotic symptoms (paranoia and hallucinations) and perception of the COVID-19 pandemic and government measures, level of activity, isolation, emotion regulation, cognitive bias and negative affect at Time 1.
- Determine which factors predict psychotic symptoms one week later and one month later.
- Explore changes across time on these measures.
Methodology:
The entire study will be conducted online. Participants will be assessed at baseline_ T1: Peak of the COVID-19 pandemic; T2: 1 week after T1; T3: 1 month after T1.
Participants will provide their informed consent. At these assessment moments, they will complete a set of self-report measures assessing COVID-19 related psychological aspects, emotion regulation, current levels of activity, cognitive bias, as well as paranoid ideation and hallucinatory experiences.
- Participants will create their own ID code (so the investigators can then match their data) and when providing their informed consent to the study they would give us their email addresses so the investigators could contact them to fill out the measures in the 2nd/3rd assessment moment
Sample size:
The investigators have not set a minimum/maximum sample size for this study. The study will remain open until the end of the self-isolation period in France. The investigators hope to recruit at least 600 participants.
List of self-report measures:
- Behavioral activation for Depression Scale
- The UCLA Loneliness Scale
- The Brief Experiential Avoidance Questionnaire
- Cognitive Emotional Regulation Questionnaire
- items measuring cognitive restructuring and catastrophisation
- Repetitive Thinking Questionnaire
- Cognitive bias questionnaire for Psychosis
- Depression Anxiety and Stress Scale
- Paranoia Scale
- Cardiff Anomalous Perceptions Scale
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- UH Montpellier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- Individuals from the general population with or without a mental disorder
- French native speaker
- Majority 18 years and more
Exclusion criteria:
- Patient refusing to participate in research
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total score of the Cardiff Anomalous Perceptions Scale (CAPS)
Time Frame: inclusion, 1 week after inclusion and 1 month after inclusion
|
The CAPS is a 32-item self-report scale designed to measure perceptual anomalies and hallucinatory experience that has already been validated in clinical and nonclinical populations.
Each of the 32 items involves a question related to a specific hallucinatory experience to which the participant can answer 'yes' or 'no'.
If the participant answers 'yes' they are asked to rate how distressing, how intrusive and how often the experience occurs on separate 1-5 rated Likert scales.
The scale total is calculated as the total number items responded to with 'yes' (possible range 0-32) and the subscale totals are calculated as the total of the subscale items (possible range 0-160)
|
inclusion, 1 week after inclusion and 1 month after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Paranoia Scale
Time Frame: inclusion, 1 week after inclusion and 1 month after inclusion
|
Paranoia Scale : this self-report scale is widely used in the assessment of paranoia in the general population. The scale is comprised of a set of 20 items, answered in a Likert-like scale ranging from 1 (never) to 5 (always). Scores can vary between 20 and 100, where higher scores indicate greater paranoid ideation |
inclusion, 1 week after inclusion and 1 month after inclusion
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL20_0225
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Disorder
-
Vincent AgyapongNova Scotia Health Authority; Dalhousie UniversityRecruitingGeneralized Anxiety Disorder | Major Depressive Disorder | Mental Health Wellness 1Canada
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophrenia | Major Depressive Disorder | Mental Disorder | Bipolar I DisorderUnited States
-
Brigham and Women's HospitalRecruitingDepression | Mood Disorders | Depressive Disorder, Major | Psychiatric Disorder | Mental DisorderUnited States
-
Queen's UniversityCompleted
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
University of OuluCompletedSeasonal Affective Disorder (SAD)Finland
-
Brigham and Women's HospitalNot yet recruitingDepression | PTSD | Mood Disorders | Anxiety Disorders | OCD | Major Depressive Disorder | Psychiatric Disorder | Mental Disorder
-
H. Lundbeck A/SCompletedMajor Depression DisorderGermany, United States, Estonia, Finland, Poland
-
GlaxoSmithKlineCompleted